EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Cell-Based Potency Assay for Determining the Relative Potency of Botulinum Neurotoxin A Preparations Using Manual and Semi-Automated Procedures

F Mark Dunning, Sara Hendrickson, Serena Wolfe, Dan Harding, Theresa Geurs, Timothy M Piazza, Thomas A Little, Ward C Tucker iD

Toxins · 15.01.2026 · 18 (1) · 45

DOI: 10.3390/toxins18010045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxins, online erschienen am 15.01.2026. Verfasst von F Mark Dunning und 7 weiteren Autor:innen. Beteiligte Einrichtung: BioSentinel Inc., 505 S. Rosa Road, Madison, WI 53719, USA. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Biological Assay. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell-based potency assays (CBPAs) are required for the potency testing and commercial release of botulinum neurotoxin (BoNT)-based drug products. These CBPAs must account for the toxin’s biological activities while meeting regulatory guidelines for precision and accuracy. Here, studies describe the characterization and qualification of the BoSapient CBPA and demonstrate that it is fit for use as a relative potency assay for BoNT/A-containing samples. The CBPA is operated in a 96-well plate format and relies upon the fluorescence emissions of a reporter that directly responds to BoNT/A activity. The BoSapient cell line expresses the BoNT/A-receptors SV2 and complex gangliosides, is responsive only to intact BoNT/A, and can robustly detect picomolar and sub-picomolar BoNT/A quantities, making the CBPA appropriate for quantifying BoNT/A-based drug products. The cell line was passaged 30 times without significant loss of reporter expression or BoNT/A sensitivity. Manual and semi-automated CBPA methods were developed and qualified according to regulatory guidelines and shown to have low bias (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ABiological AssayAnimalsHumansCell LineAutomation

Stichwörter der Autor:innen

botulinum neurotoxincell-based potency assaylaboratory automationparallel line analysisrelative potency

Substanzen

Botulinum Toxins, Type A

Autor:innen und Institutionen

  • BioSentinel Inc., 505 S. Rosa Road, Madison, WI 53719, USA.
  • BioAssay Sciences, Highland, UT 84003, USA.

ORCID-Profile: Ward C Tucker

Zitieren

APA

Dunning, F. M., Hendrickson, S., Wolfe, S., Harding, D., Geurs, T., Piazza, T. M., Little, T. A., & Tucker, W. C. (2026). A Cell-Based Potency Assay for Determining the Relative Potency of Botulinum Neurotoxin A Preparations Using Manual and Semi-Automated Procedures. Toxins, 18(1), 45. https://doi.org/10.3390/toxins18010045

Vancouver

Dunning FM, Hendrickson S, Wolfe S, Harding D, Geurs T, Piazza TM, et al. A Cell-Based Potency Assay for Determining the Relative Potency of Botulinum Neurotoxin A Preparations Using Manual and Semi-Automated Procedures. Toxins. 2026;18(1):45. doi:10.3390/toxins18010045

BibTeX
@article{Dunning2026,
  author = {Dunning, F Mark and Hendrickson, Sara and Wolfe, Serena and Harding, Dan and Geurs, Theresa and Piazza, Timothy M and Little, Thomas A and Tucker, Ward C},
  title = {A Cell-Based Potency Assay for Determining the Relative Potency of Botulinum Neurotoxin A Preparations Using Manual and Semi-Automated Procedures},
  journal = {Toxins},
  year = {2026},
  volume = {18},
  number = {1},
  pages = {45},
  doi = {10.3390/toxins18010045}
}
Kostenlos starten →